Specifically, studies suggest anti‐VEGF may increase the risk of neurodevelopmental disabilities and pulmonary hypertension compared to laser therapy (Morin et al., 2016; Natarajan et al., 2019; Nitkin et al., 2022). Here, VEGFA is linked to pulmonary arterial hypertension.